These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 21425164)

  • 41. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Roadmap for implementation of quality by design (QbD) for biotechnology products.
    Rathore AS
    Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development, validation and transfer of a near infrared method to determine in-line the end point of a fluidised drying process for commercial production batches of an approved oral solid dose pharmaceutical product.
    Peinado A; Hammond J; Scott A
    J Pharm Biomed Anal; 2011 Jan; 54(1):13-20. PubMed ID: 20801599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new definition of pharmaceutical quality: assembly of a risk simulation platform to investigate the impact of manufacturing/product variability on clinical performance.
    Short SM; Cogdill RP; D'Amico F; Drennen JK; Anderson CA
    J Pharm Sci; 2010 Dec; 99(12):5046-59. PubMed ID: 20574996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
    Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
    J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: a review.
    Tomba E; Facco P; Bezzo F; Barolo M
    Int J Pharm; 2013 Nov; 457(1):283-97. PubMed ID: 24016743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quality Assurance and Quality Control, Part 2.
    Akers MJ
    Int J Pharm Compd; 2015; 19(3):215-21. PubMed ID: 26714362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dry-heat Depyrogenation Ovens for Pharmaceutical Compounding Facilities.
    Weller T; Kragseth R; Dullinger R; Illum H; Perry A
    Int J Pharm Compd; 2015; 19(3):182-92. PubMed ID: 26714359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A quality by design approach for longitudinal quality attributes.
    Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
    J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Continuous processing and the applications of online tools in pharmaceutical product manufacture: developments and examples.
    Ooi SM; Sarkar S; van Varenbergh G; Schoeters K; Heng PW
    Ther Deliv; 2013 Apr; 4(4):463-70. PubMed ID: 23557287
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations.
    Norwood DL; Paskiet D; Ruberto M; Feinberg T; Schroeder A; Poochikian G; Wang Q; Deng TJ; DeGrazio F; Munos MK; Nagao LM
    Pharm Res; 2008 Apr; 25(4):727-39. PubMed ID: 18183477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using tolerance intervals for assessment of pharmaceutical quality.
    Dong X; Tsong Y; Shen M; Zhong J
    J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics.
    Kretsinger J; Frantz N; Hart SA; Kelley WP; Kitchen B; Novick S; Rellahan B; Stranges D; Stroop CJM; Yin P; Gastens MH
    J Pharm Sci; 2019 Apr; 108(4):1442-1452. PubMed ID: 30528942
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
    Zhuang Y; Chen D; Sharma A; Xu Z
    AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Review of the Aging Process and Facilities Topic.
    Jornitz MW
    PDA J Pharm Sci Technol; 2015; 69(4):553-6. PubMed ID: 26242790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of drug product development.
    Narayan P
    Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmaceutical applications of vibrational chemical imaging and chemometrics: a review.
    Gendrin C; Roggo Y; Collet C
    J Pharm Biomed Anal; 2008 Nov; 48(3):533-53. PubMed ID: 18819769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving drug manufacturing with process analytical technology.
    Rodrigues LO; Alves TP; Cardoso JP; Menezes JC
    IDrugs; 2006 Jan; 9(1):44-8. PubMed ID: 16374733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.